5, 10, and 15 mg, which are achieved following a starting dose of 2.5 mg given for 4 weeks, followed by stepwise increments of 2.5 mg every 4 weeks to attain the final dose of 5, 10, or 15 mg
Side effects: While generally similar across the class (nausea, vomiting, diarrhea), the intensity and duration can vary between medications
Medicare (Part D and Medicare Advantage) : For Medicare beneficiaries, coverage depends on the prescribed indication: For OSA: Zepbound received FDA approval in December 2024 to treat moderatetosevere OSA in people with a body mass index (BMI) of 30 or higher
Results of the SELECT trial on major adverse cardiovascular events with semaglutide 2.4 mg
At 24 weeks, the same group was already at 17.5 percent reduction, or 18.7 kilograms